Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04857372 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 137 | — | — | Oct 21, 2021 | Sep 4, 2026 | Sep 19, 2025 | 16 | United States, Australia +9 |
Safety and tolerability of IAG933
Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933
Tolerability of IAG933
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Malignant pleural mesothelioma |
| Group 2 | EXPERIMENTAL | NF2 truncating mutations or deletions |
| Group 3 | EXPERIMENTAL | Solid tumors with functional YAP/TAZ fusions |
| Group 4 | EXPERIMENTAL | Non-pleural mesothelioma |
| Name | Type | Description |
|---|---|---|
| IAG933 | DRUG | Capsule |
Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Male or female patients must be ≥ 18 years of age. 3. Dose escalation part: patients with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma...